^
Association details:
| Biomarker: | CXCL12 expression + PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
33P - Changes in serum cytokine CXCL12 level can predict the survival of patients with non-small-cell lung cancer receiving anti-PD-1 treatment
Published date:
12/01/2022
Excerpt:
CXCL12 levels in the top 33% (1/3) was a poor prognostic factor for durable clinical benefit (DCB, 23.5% vs. 72.1%, p<0.001), PFS (3.76 vs. 14.4 months; p<0.001) and OS (12.2 vs. 44.84 months; p=0.008), and a signature comprising PD-L1<1% and top 33% CXCL12 was associated with lowest ORR (27.3% vs. 73.7%, p<0.001), DCB (27.3% vs. 73.7%, p<0.001) and the worst mPFS (2.44 vs. 25.35 months, p<0.001) and mOS (11.97 vs. 44.84 months, p=0.007)....Our findings suggest that the combination of circulating cytokine CXCL12 level and PD-L1 status can predict survival of advanced NSCLC patients treated with ICIs.
